ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

trastuzumab pamirtecan

Also written as “DB-1303/BNT323”, “BNT323/DB-1303” and “BNT323”.

Its studies are mostly in Breast Neoplasms · Endometrial Neoplasms · Neoplasm Metastasis, led by 2 companies.

Drug pageTrastuzumab pamirtecan: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 25, 20235 company-led studies, 5 open or runningNext primary completion: Aug 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
DualityBioits history only33 open or runningphase 3since Aug 25, 2023Nov 11, 2021Aug 2027phase 2 · NCT05150691
BioNTech22 open or runningphase 3since Mar 25, 2024Mar 25, 2024Mar 2028phase 3 · NCT06340568

Also a collaborator on its studies: BioNTech (Shanghai) Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of BioNTech only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 25, 2024First study: phase 3 study in Endometrial NeoplasmsFirst studyNCT06340568 · 480 planned · United States, Argentina, Australia and more
  2. Aug 11, 2024Named trastuzumab pamirtecanINNProposed as its International Nonproprietary Name in WHO's List 131 · before, BNT323
  3. Feb 10, 2025Phase 2 study in Breast NeoplasmsNCT06827236 · 380 planned · United States, Australia, Canada and more

Ahead

  1. Mar 2028Primary completion: phase 3 study in Endometrial NeoplasmsNCT06340568
  2. Aug 2029Primary completion: phase 2 study in Breast NeoplasmsNCT06827236

TargetBeta

ERBB2 →read by rule
“An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 2 BioNTech leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06827236Breast Neoplasms · United States, Australia, Canada and more2RecruitingAug 2029380
NCT06340568Endometrial Neoplasms · United States, Argentina, Australia and more3RecruitingMar 2028480

How it is read

Names in the registry

  • “DB-1303/BNT323”, 3 entries
  • “BNT323/DB-1303”, 1 entry
  • “BNT323”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.